Esperion Therapeutics (ESPR) News Today $2.21 -0.05 (-2.21%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Esperion Therapeutics, Inc. (NASDAQ:ESPR) Short Interest UpdateEsperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) was the target of a large increase in short interest in December. As of December 31st, there was short interest totalling 32,350,000 shares, an increase of 27.0% from the December 15th total of 25,470,000 shares. Currently, 16.6% of the company's stock are short sold. Based on an average daily volume of 5,630,000 shares, the short-interest ratio is currently 5.7 days.January 18 at 8:06 PM | marketbeat.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Stock Position Lifted by Barclays PLCBarclays PLC lifted its stake in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 99.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 309,671 shares of the biopharJanuary 18 at 3:11 AM | marketbeat.comBank of America Securities Reaffirms Their Sell Rating on Esperion (ESPR)January 16, 2025 | markets.businessinsider.comEsperion stock falls on higher operating expense forecastJanuary 16, 2025 | msn.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Rating of "Hold" from BrokeragesShares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) have received an average rating of "Hold" from the five research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommenJanuary 12, 2025 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Esperion Therapeutics (NASDAQ:ESPR)January 12, 2025 | americanbankingnews.comEsperion’s Strategic International Expansion and Revenue Growth Justify Buy RatingJanuary 10, 2025 | markets.businessinsider.comEsperion Therapeutics' (ESPR) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating on shares of Esperion Therapeutics in a report on Friday.January 10, 2025 | marketbeat.com3 Small-Cap Healthcare Stocks With Big Upside PotentialJanuary 9, 2025 | stocknews.comEsperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 2, 2025 | markets.businessinsider.com3 Healthcare Innovators with Analyst-Endorsed UpsideDecember 26, 2024 | stocknews.comPublic Employees Retirement System of Ohio Buys New Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR)Public Employees Retirement System of Ohio purchased a new position in Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 367,373 shares of the biopharmaceutical company's stock,December 21, 2024 | marketbeat.comWellington Management Group LLP Acquires 241,512 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR)Wellington Management Group LLP boosted its holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 66.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 602,936 shares of the biopharmaceutical company's stockDecember 20, 2024 | marketbeat.com3 High-Growth Biotech Stocks to WatchDecember 19, 2024 | stocknews.comPaul Choi Assigns Hold Rating to Esperion Due to Market Uncertainty and Pipeline ChallengesDecember 19, 2024 | markets.businessinsider.comAnalysts Offer Predictions for ESPR FY2024 EarningsEsperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for Esperion Therapeutics in a report released on Tuesday, December 17th. Cantor Fitzgerald analyst K. Kluska anticipates that the biopharmaceutical company will earnDecember 19, 2024 | marketbeat.comEsperion closes refinancing transactionsDecember 19, 2024 | markets.businessinsider.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Given Average Recommendation of "Moderate Buy" by AnalystsShares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the four research firms that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and three hDecember 18, 2024 | marketbeat.comEsperion Therapeutics (NASDAQ:ESPR) Coverage Initiated at The Goldman Sachs GroupThe Goldman Sachs Group started coverage on shares of Esperion Therapeutics in a research report on Wednesday. They set a "neutral" rating and a $4.00 price objective for the company.December 18, 2024 | marketbeat.comEsperion Strengthens Balance Sheet with Closing of Significant Refinancing TransactionsDecember 18, 2024 | globenewswire.comCantor Fitzgerald Initiates Coverage of Esperion Therapeutics (ESPR) with Overweight RecommendationDecember 17, 2024 | msn.comEsperion initiated with an Overweight at Cantor FitzgeraldDecember 17, 2024 | markets.businessinsider.comEsperion Therapeutics (NASDAQ:ESPR) Coverage Initiated at Cantor FitzgeraldCantor Fitzgerald initiated coverage on Esperion Therapeutics in a report on Tuesday. They set an "overweight" rating and a $8.00 price objective on the stock.December 17, 2024 | marketbeat.comEsperion’s Strategic Debt Refinancing Boosts Financial Stability and Investor AppealDecember 15, 2024 | markets.businessinsider.comEsperion Therapeutics (NASDAQ:ESPR) Given Buy Rating at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $6.00 price objective on shares of Esperion Therapeutics in a research note on Friday.December 13, 2024 | marketbeat.comEsperion Announces $210 Million Convertible Debt FinancingDecember 13, 2024 | globenewswire.comEsperion’s Strategic Expansion and International Growth Justify Buy RatingDecember 12, 2024 | markets.businessinsider.comEsperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in IsraelDecember 12, 2024 | globenewswire.comEsperion’s Strategic Pipeline Advancements and Market Recovery Drive Buy Rating Amidst Cholesterol CompetitionDecember 11, 2024 | markets.businessinsider.comWill The Long Awaited Breakout For Esperion Therapeutics Hold?December 8, 2024 | seekingalpha.comAnson Funds Management LP Acquires New Shares in Esperion Therapeutics, Inc. (NASDAQ:ESPR)Anson Funds Management LP acquired a new stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 327,110 shares of the biopharmaceutical company's stock, valued at approximateDecember 8, 2024 | marketbeat.comEsperion Therapeutics (NASDAQ:ESPR) Shares Gap Up - Time to Buy?Esperion Therapeutics (NASDAQ:ESPR) Shares Gap Up - Here's What HappenedDecember 6, 2024 | marketbeat.comParkman Healthcare Partners LLC Has $1.49 Million Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR)Parkman Healthcare Partners LLC lessened its position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 21.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 903,140 shares of the biopharmaceutiDecember 4, 2024 | marketbeat.comEsperion’s Global Expansion and Strategic Growth: A Compelling Buy OpportunityDecember 2, 2024 | markets.businessinsider.comZacks Research Issues Pessimistic Outlook for ESPR EarningsEsperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Research analysts at Zacks Research cut their FY2025 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research report issued on Thursday, November 28th. Zacks Research analyst K. Das now forecasts that the biophaDecember 2, 2024 | marketbeat.comEsperion Therapeutics, Inc. (NASDAQ:ESPR) Shares Acquired by Wasatch Advisors LPWasatch Advisors LP lifted its holdings in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 38.4% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 23,346,013 shares of the biopharmaceutical company's stock after purcDecember 1, 2024 | marketbeat.comEsperion Therapeutics (NASDAQ:ESPR) Stock Price Up 8.7% - What's Next?Esperion Therapeutics (NASDAQ:ESPR) Trading 8.7% Higher - Here's WhyNovember 29, 2024 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Increases Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR)Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 71.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 711,278 shares of the biNovember 28, 2024 | marketbeat.comEsperion Therapeutics (NASDAQ:ESPR) Earns "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $16.00 price target on shares of Esperion Therapeutics in a research note on Wednesday.November 27, 2024 | marketbeat.comPositive Outlook for Esperion Due to Strong Clinical Data and Strategic ExpansionNovember 26, 2024 | markets.businessinsider.comEsperion announces Otsuka submitted NDA to Japanese MHLW for bempedoic acidNovember 26, 2024 | markets.businessinsider.comEsperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare ConferenceNovember 24, 2024 | uk.finance.yahoo.comEsperion Therapeutics (ESPR) Q3 2024 Financials: Key Highlights and Future OutlookNovember 22, 2024 | theglobeandmail.comBuy Rating Affirmed for Esperion Due to Bempedoic Acid’s Clinical Efficacy in Recent TrialsNovember 20, 2024 | markets.businessinsider.comHC Wainwright Reiterates Buy Rating for Esperion Therapeutics (NASDAQ:ESPR)HC Wainwright restated a "buy" rating and issued a $16.00 price target on shares of Esperion Therapeutics in a report on Tuesday.November 19, 2024 | marketbeat.comEsperion highlights exploratory data from CLEAR outcomes trial of NexletolNovember 19, 2024 | markets.businessinsider.comEsperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024November 18, 2024 | globenewswire.comEsperion Therapeutics (NASDAQ:ESPR) Cut to "Hold" at StockNews.comStockNews.com lowered shares of Esperion Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday.November 15, 2024 | marketbeat.comEsperion Therapeutics: Growth Initiatives Are Paying Off - BuyNovember 13, 2024 | seekingalpha.comHC Wainwright Has Positive Estimate for ESPR FY2025 EarningsEsperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Equities research analysts at HC Wainwright boosted their FY2025 earnings per share (EPS) estimates for Esperion Therapeutics in a report released on Thursday, November 7th. HC Wainwright analyst J. Pantginis now expects that the biopharmaNovember 11, 2024 | marketbeat.com Get Esperion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. Email Address ESPR Media Mentions By Week ESPR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ESPR News Sentiment▼0.560.44▲Average Medical News Sentiment ESPR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ESPR Articles This Week▼44▲ESPR Articles Average Week Get Esperion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Belite Bio News Today Disc Medicine News Today Amphastar Pharmaceuticals News Today Wave Life Sciences News Today Apogee Therapeutics News Today Indivior News Today Galapagos News Today Structure Therapeutics News Today Arcutis Biotherapeutics News Today Evotec News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ESPR) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Esperion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ESPR Stock Alerts